These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1205 related articles for article (PubMed ID: 31159582)

  • 1. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator.
    Packer M
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e007430. PubMed ID: 31159583
    [No Abstract]   [Full Text] [Related]  

  • 3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Heart Failure Patient with CKD.
    Banerjee D; Rosano G; Herzog CA
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1131-1139. PubMed ID: 33495289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.
    Bristow MR; Saxon LA; Feldman AM; Mei C; Anderson SA; DeMets DL
    JACC Heart Fail; 2016 Jul; 4(7):521-535. PubMed ID: 27289408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
    Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
    Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews.
    Al-Gobari M; Al-Aqeel S; Gueyffier F; Burnand B
    BMJ Open; 2018 Jul; 8(7):e021108. PubMed ID: 30056380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
    Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
    Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis.
    Gama F; Ferreira J; Carmo J; Costa FM; Carvalho S; Carmo P; Cavaco D; Morgado FB; Adragão P; Mendes M
    J Am Heart Assoc; 2020 Apr; 9(8):e015177. PubMed ID: 32290732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
    Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction.
    Batchelor RJ; Nan Tie E; Romero L; Hopper I; Kaye DM
    Am J Cardiol; 2023 Feb; 188():52-60. PubMed ID: 36473305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020.
    Karlström P; Pivodic A; Dahlström U; Fu M
    Clin Res Cardiol; 2024 Sep; 113(9):1355-1368. PubMed ID: 39186181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.
    Packer M
    JACC Heart Fail; 2019 Oct; 7(10):902-906. PubMed ID: 31521684
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.
    de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J
    Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66).
    Foo FS; Lee M; Poppe KK; Clare GC; Stiles MK; Gavin A; Webber M; Jackson R; Kerr AJ
    Heart Lung Circ; 2022 Nov; 31(11):1531-1538. PubMed ID: 35999128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.